Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy

BACKGROUND: Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate neoepitope-reactive T-cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Reimann, Hannah, Nguyen, Andrew, Sanborn, J Zachary, Vaske, Charles J, Benz, Stephen C, Niazi, Kayvan, Rabizadeh, Shahrooz, Spilman, Patricia, Mackensen, Andreas, Ruebner, Matthias, Hein, Alexander, Beckmann, Matthias W, van der Meijden, Edith D, Bausenwein, Judith, Kretschmann, Sascha, Griffioen, Marieke, Schlom, Jeffrey, Gulley, James L, Lee, Karin L, Hamilton, Duane H, Soon-Shiong, Patrick, Fasching, Peter A, Kremer, Anita N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237736/
https://www.ncbi.nlm.nih.gov/pubmed/34172517
http://dx.doi.org/10.1136/jitc-2021-002605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237736/
https://www.ncbi.nlm.nih.gov/pubmed/34172517
http://dx.doi.org/10.1136/jitc-2021-002605

Ejemplares similares